Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

963
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
963
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

828
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
828
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

825
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
825
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.2K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.2K
Analgesia and Pain Management01:25

Analgesia and Pain Management

1.5K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
1.5K
Management of Insomnia01:19

Management of Insomnia

542
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
542

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Estimating treatment effects on health utility scores for patients living with migraine: a post hoc analysis of the DELIVER trial.

Expert review of pharmacoeconomics & outcomes research·2023
Same author

Migraine: from pathophysiology to treatment.

Journal of neurology·2023
Same author

Evaluating migraine with typical aura with neuroimaging.

Frontiers in human neuroscience·2023
Same author

Non-invasive neuromodulation of the cervical vagus nerve in rare primary headaches.

Frontiers in pain research (Lausanne, Switzerland)·2023
Same author

Effectiveness and safety profile of greater occipital nerve blockade in cluster headache: a systematic review.

Journal of neurology, neurosurgery, and psychiatry·2023
Same author

Patient-reported experiences with migraine-related cognitive symptoms: Results of the MiCOAS qualitative study.

Headache·2023

Related Experiment Video

Updated: Jan 17, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.7K

Migraine: advances in treatment.

Usman Ashraf1, Peter J Goadsby2

  • 1NIHR King's Clinical Research Facility, SLaM Biomedical Research Centre, King's College London, London, UK; Wolfson Sensory, Pain and Regeneration Centre, King's College London, London, UK.

Trends in Molecular Medicine
|September 19, 2025
PubMed
Summary

New migraine treatments target calcitonin gene-related peptide and serotonin 5HT1F receptors. Research explores novel therapies for non-responders, aiming for precision migraine management.

Keywords:
CGRPPACAPmigrainepathophysiologyserotonintreatments

More Related Videos

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders
05:49

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

Published on: November 1, 2024

1.2K
Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache
05:40

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Published on: July 29, 2021

9.6K

Related Experiment Videos

Last Updated: Jan 17, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.7K
Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders
05:49

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

Published on: November 1, 2024

1.2K
Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache
05:40

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Published on: July 29, 2021

9.6K

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Migraine pathophysiology understanding has driven new drug development.
  • Calcitonin gene-related peptide (CGRP) and its receptor are key targets.
  • Serotonin 5HT1F receptor agonists (ditans) offer acute migraine management, bypassing risks of 5HT1B/1D agonists (triptans).

Purpose of the Study:

  • To review current and emerging therapies for migraine.
  • To highlight limitations of existing treatments and unmet needs.
  • To discuss the potential for precision medicine in migraine.

Main Methods:

  • Literature review of pathophysiology and therapeutic targets in migraine.
  • Analysis of efficacy and safety data for CGRP and ditan therapies.
  • Exploration of novel and emerging therapeutic targets.

Main Results:

  • CGRP-targeting therapies and ditans show efficacy in acute migraine.
  • A significant portion of patients do not respond to current therapies.
  • Emerging targets include pituitary adenylate cyclase activating polypeptide, amylin, adrenomedullin, KATP channels, transient receptor potential ion channels, and neuronal nitric oxide synthase.

Conclusions:

  • Despite advances, many patients remain refractory to current migraine treatments.
  • Emerging therapies offer new hope for managing difficult-to-treat migraines.
  • Understanding patient heterogeneity is crucial for developing personalized migraine management strategies.